• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, November 13, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Rapamycin for longevity — Opinion article

Bioengineer by Bioengineer
October 16, 2019
in Health
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Mikhail V. Blagosklonny
blagosklonny@oncotarget.com


The scientist discusses several reasons, including fear of the actual and fictional side effects of rapamycin, everolimus and other clinically-approved drugs, arguing that no real side effects preclude their use as anti-aging drugs today.

They go on to discuss why it is more dangerous not to use anti-aging drugs than to use them and how rapamycin-based drug combinations have already been implemented for potential life extension in humans.

Dr. Mikhail V. Blagosklonny from the Cell Stress Biology Lab, at Roswell Park Cancer Institute, in Buffalo, NY 14263 USA said, “In one short-lived mutant strain of mice, the mTOR inhibitor rapamycin extends maximum life span nearly three-fold.”

The overwhelming evidence suggests that rapamycin is a universal anti-aging drug that is, it extends lifespan in all tested models from yeast to mammals, suppresses cell senescence and delays the onset of age-related diseases, which are manifestations of aging.

Although rapamycin may reverse some manifestations of aging, it is more effective at slowing down aging than reversing it.

Therefore, rapamycin will be most effective when administered at the pre-disease, or even pre-pre-disease stages of age-related diseases.

Even if one or a few age-related diseases renders aging unhealthy, other potential diseases are still at pre-disease stages, and anti-aging drugs may delay their development.

In addition to rapamycin/everolimus, the anti-aging formula metformin, aspirin, ACE inhibitors, angiotensin receptor blockers and PDE5 inhibitors, each of which can prevent or treat more than one age-related disease.

Blagosklonny concluded, “There is no shortage of potential patients who unfortunately already employ self-medication with rapamycin, but there is a shortage of physicians to treat them.”

###

Full Text – https://www.aging-us.com/article/102355/text

Correspondence to: Mikhail V. Blagosklonny email: Blagosklonny@rapalogs.com

Keywords: rapamycin, rapalogs, metformin, aging, anti-aging, fasting, lifespan, health span

Media Contact

media@impactjournals.com

716-449-4773

Media Contact
RYAN JAMES JESSUP
RYANJAMESJESSUP@IMPACTJOURNALS.COM
202-638-9720

Original Source

https://www.aging-us.com/news_room/rapamycin-for-longevity-opinion-article

Related Journal Article

http://dx.doi.org/10.18632/aging.102355

Tags: GerontologyMedicine/Health
Share13Tweet8Share2ShareShareShare2

Related Posts

Clinical Trial Demonstrates Feasibility of Ketogenic Metabolic Therapy for Severe Psychiatric Disorders

Clinical Trial Demonstrates Feasibility of Ketogenic Metabolic Therapy for Severe Psychiatric Disorders

November 13, 2026
Rowers Improve Race Times Without Matching Shifts in Standard Training Biomarkers

Rowers Improve Race Times Without Matching Shifts in Standard Training Biomarkers

November 13, 2026

Insulin Resistance Emerges as Sentinel Driver Across the Cardiometabolic Disease Spectrum

November 13, 2026

Preclinical Meta-Analysis Evaluates Naringenin for Myocardial Ischemia-Reperfusion Injury

November 13, 2026
Please login to join discussion

POPULAR NEWS

  • Researchers Review SQSTM1 and p62 Dual Roles Across Cancer Development

    Researchers Review SQSTM1 and p62 Dual Roles Across Cancer Development

    29 shares
    Share 12 Tweet 7
  • Insulin Resistance Emerges as Sentinel Driver Across the Cardiometabolic Disease Spectrum

    29 shares
    Share 12 Tweet 7
  • Fish-Derived Probiotic Enhances Growth and Disease Defense in Farmed Tench

    29 shares
    Share 12 Tweet 7
  • Preclinical Meta-Analysis Evaluates Naringenin for Myocardial Ischemia-Reperfusion Injury

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Clinical Trial Demonstrates Feasibility of Ketogenic Metabolic Therapy for Severe Psychiatric Disorders

DNA Barcoding Identifies More Than 60,000 Insect Species Across California

Neanderthal Heels Showed Flat Feet Adapted for Stability

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 86 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.